Information Provided By:
Fly News Breaks for November 7, 2019
AERI
Nov 7, 2019 | 06:44 EDT
Mizuho analyst Difei Yang lowered her price target for Aerie Pharmaceuticals to $54 from $63 saying management lowered guidance a second time this year due to recent volume trends, which continue to be negatively impacted by insurance coverage uptake. The analyst, however, continues to see potential long-term, especially when considering the "strength and benefits" of Rhopressa plus Rocklatan in the clinical setting. As such, Yang keeps a Buy rating on Aerie Pharmaceuticals.
News For AERI From the Last 2 Days
There are no results for your query AERI